Pluri Inc. entered into a securities purchase agreement on August 26, 2026, for a registered direct offering of 1,200,000 common shares and pre-funded warrants to purchase up to 1,028,940 additional shares. The transaction includes a concurrent private placement of common warrants exercisable at $1.65 per share for 2,228,940 total shares. Net proceeds are expected to be approximately $2,984,808 after fees and expenses. The offering is expected to close on August 28, 2026. Pluri Inc. operates in the advanced technology sector, specializing in semiconductor manufacturing equipment.

Pluri Inc.'s indirect majority-owned subsidiary, Ever After Foods Ltd., entered into a share purchase agreement to acquire Fishway BV and its shareholders. The transaction involves issuing EAF ordinary shares in exchange for all outstanding Fishway capital, alongside a $2.0 million Simple Agreement for Future Equity (SAFE) investment from certain sellers. Pluri Inc. is not a party to the agreements but currently holds approximately 69% of EAF; post-closing, its indirect stake is expected to dilute to roughly 58%. The deal aims to support EAF's European strategy through Fishway's Belgian presence and cultivated seafood research capabilities. Closing is anticipated within 30 days subject to customary conditions. Pluri Inc. operates in the biotechnology sector, developing cellular agriculture technologies for food production.

Pluri Inc. is in active discussions with the European Investment Bank (EIB) regarding a potential resolution for its €50 million finance agreement, which was scheduled to be repaid on June 1, 2026. The EIB has indicated that discussions are advancing constructively and are subject to its internal approval process and legal review. Pluri Inc. operates in the biotechnology/cell therapy industry and develops cell-based products for therapeutic and therapeutic-related applications.

Pluri Inc. received a written notice from Nasdaq indicating it is not in compliance with the minimum market value of listed securities requirement of $35 million. The company has an initial 180-day compliance period ending January 4, 2027, to regain compliance. Pluri Inc. is a biotechnology company that develops cell-based products for the medical and food industries.

Pluri Inc. entered into an Advance Subscription Agreement with Chutzpah Holdings LP on June 14, 2026, receiving $1,250,000 in advance payment for a future financing round expected to be completed by August 14, 2026. Additionally, following the 2026 Annual Meeting of Shareholders, shareholder votes resulted in the non-re-election of Eitan Ajchenbaum to the Board, and the Board subsequently appointed Doron Shorrer to fill the vacancy. Pluri Inc. operates in the biotechnology/life sciences industry, focusing on on-demand cell therapy products.